The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

TechMARK movers: Vodafone goes ex-dividend

Wed, 17th Nov 2010 13:38

TechMARK's decline will undoubtedly have been influenced by Vodafone going ex-dividend. Mobile phone networks operator Vodafone is paying an interim dividend of 2.85p a share, which is similar to the size of the fall in the share price. Vodafone is the biggest company in TechMARKPositive news from the second biggest company in TechMARK, GlaxoSmithKline, which is around three-quarters of Vodafone's size, will have helped to offset the ex-dividend effect.Panmure Gordon has upgraded its forecasts for GlaxoSmithKline following the endorsement of potential Lupus drug Benlysta by an FDA advisory committee by a margin of 13-2. The broker has upgraded 2013 earnings by 1.6% and 2014 earnings by 1.5%.Chip designer Imagination Technologies is building up its war chest with a £37.8m share placing at 310p a share. The share price has dipped below the placing price.The cash will be used to fund acquisitions. The first is HelloSoft, a US voice over internet protocol (VOIP) operator. Imagination is paying a maximum of $47m for Hellosoft, a company that has technology patents that are complementary to Imagination's. The initial payment is $20.2m (£12.7m). The final consideration is dependent on the performance of Hellosoft over the next three years.Interim figures will be published on 14 December. Biotech Phytopharm has jumped on the back of the commencement of a phase II study into its Parkinson's disease treatment Cogane. The results of the study should be available by end of 2012.FTSE TechMARK - RisersPhytopharm (PYM) 7.93p +11.22%Ark Therapeutics Group (AKT) 4.30p +4.88%E2V Technologies (E2V) 88.50p +2.31%Oxford Biomedica (OXB) 9.80p +1.14%AEA Technology Group (AAT) 5.25p +0.96%Xaar (XAR) 216.00p +0.93%Emblaze Ltd. (BLZ) 47.00p +0.53%Kewill (KWL) 93.25p +0.27%FTSE TechMARK - FallersAsterand (ATD) 10.25p -12.77%Imagination Technologies Group (IMG) 309.00p -4.92%Cable & Wireless Worldwide (CW.) 66.55p -3.41%Renovo Group (RNVO) 33.50p -2.90%Sepura (SEPU) 42.00p -2.89%Promethean World (PRW) 77.75p -2.51%Puricore (PURI) 50.50p -2.42%Vodafone Group (VOD) 167.00p -2.02%KCOM Group (KCOM) 49.00p -2.00%Cobham (COB) 201.20p -1.61%

Related Shares

More News
2 Jan 2020 07:37

Apple inks licensing deal with Imagination Technologies

(Sharecast News) - Apple has inked a new supply deal with Imagination Technologies for its graphics processing units.

19 Mar 2018 15:03

Total renewables unit targets Africa's power-starved mining sector

By Joe Bavier ABIDJAN, March 19 (Reuters) - Total's renewable energy unit said on Monday it had opened the world's largest solar-thermal hybrid plant ...

12 Mar 2018 14:35

CANADA STOCKS-Toronto stocks edge up, following global markets higher

March 12 (Reuters) - Canada's main stock index rose modestly on Monday, buoyed by improved risk appetite in global markets but declines in energy shar...

9 Mar 2018 21:24

UPDATE 1-CANADA STOCKS-TSX ends higher alongside global stocks, oil, metals

By Nichola Saminather TORONTO, March 9 (Reuters) - Canada's main stock index closed higher on Friday, lifted by strong gains in oil and metals

7 Dec 2016 09:55

Imagination Technologies boosted by Numis upgrade

(ShareCast News) - Imagination Technologies Group gained as Numis raised its rating on the stock to 'buy' from 'add' and lifted the target price to 31...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.